12 results about "Somatotropic hormone" patented technology

Disclosed are a compound shown in formula I and racemate, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same, a preparation method thereof, and a use thereof as a GHSR agonist in the preparation of a drug for the diagnosis, prevention and / or treatment of growth hormone-dependent diseases, the structure of formula I is as follows:

The application discloses a method for preparing GHR humanized animal cells by using a CRISPR system, which comprises the following steps: designing and synthesizing sgRNA; mixing the sgRNA with a Cas9 protein to form a CRISPR-Cas9 complex; constructing donor DNA containing coding sequences of a human GHR extracellular region and a rat GHR intracellular region; injecting the CRISPR-Cas9 complex and the donor DNA into the cytoplasm or nucleus of a rat fertilized ovum to knockout the coding sequence of the extracellular region of the rat-derived GHR gene and simultaneously insert the coding sequence of the extracellular region of the human-derived GHR gene into the genome, so that the GHR humanized animal cells are obtained. The application further discloses a method for constructing a GHR humanized rat model by using the CRISPR system, and application of the GHR humanized animal cells and the GHR humanized rat model obtained by the above method in drug screening, drug development or efficacy evaluation. The application can more accurately simulate the interaction between the human GHR and growth hormone and other ligands, improves the accuracy and reliability of research, and has the advantages of simple gene editing operation, high editing efficiency, strong specificity, low off-target effect and wide application range.

This invention provides single-domain antibodies or antigen-binding fragments thereof that specifically bind to growth hormone (e.g., human growth hormone), polypeptide constructs and conjugates containing said single-domain antibodies or antigen-binding fragments thereof, nucleic acid molecules encoding said single-domain antibodies or antigen-binding fragments thereof, and host cells containing them, as well as related uses. Furthermore, it provides uses of said single-domain antibodies or antigen-binding fragments thereof, polypeptide constructs, or conjugates for the purification and / or detection of growth hormone (e.g., human growth hormone).

This invention discloses the use of at least one growth-active substance selected from (a) and (b) below, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or an analogue thereof, or an analogue thereof, in the preparation of a medicament, pharmaceutical composition, or formulation for improving, correcting, alleviating, controlling, treating, or preventing ophthalmic diseases or symptoms: (a) growth hormone; (b) a growth hormone secretion stimulant. By administering an effective amount of the growth-active substance to a patient, ophthalmological conditions, especially hyperopia and related symptoms, can be significantly improved, achieving the effect of preventing and treating hyperopia, with good safety and promising clinical application prospects. This invention also provides pharmaceutical compositions, formulations, and devices containing the above-mentioned growth-active substances.

This invention provides an aptamer targeting the growth hormone receptor and its uses, the nucleotide sequence of which is shown in SEQ ID NO.1 or SEQ ID NO.2. This invention utilizes a modified SELEX technique to perform multiple rounds of screening targeting recombinant GHR protein, obtaining specific nucleic acid aptamers with high affinity for GHR (KD values ​​at the micromolar level). In vivo distribution experiments show that the fluorescently labeled aptamer can efficiently and specifically accumulate in white adipose tissue (including inguinal and gonadal fat) at the in vivo level, exhibiting excellent tissue targeting. The nucleic acid aptamer and its derivatives of this invention can be used to prepare drugs or diagnostic reagents targeting adipose tissue, for example, for the prevention or treatment of metabolic diseases such as obesity, type 2 diabetes, fatty liver, hyperlipidemia, or cardiovascular disease.

The novel compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride has high permeability, is able to cross the blood-brain barrier and shows consistent ghrelin agonist activity at the level of the central nervous system; the compound is effective in the treatment and / or prevention of medical conditions mediated by ghrelin receptors in the central nervous system. In particular, in experimental tests, the compound shows high efficacy in the treatment of neurotoxic injuries and has an effective neuroprotective action combination pattern at both central and peripheral levels. The compound is also useful in the treatment of diseases requiring a reduction in heart rate. The compound has pharmacological activity at low to moderate doses, thus showing a good therapeutic index.

The application discloses an evaluation method and system based on child growth hormone secretion data, and relates to the technical field of medical data processing.The method determines candidate points through robust outlier preliminary screening by acquiring a growth hormone concentration time sequence; extracts a concentration subsequence of a neighborhood window of the candidate points, calculates a dynamic time warping distance of the concentration subsequence from a preset pulse sequence by using a dynamic time warping algorithm, and converts the dynamic time warping distance into a pulse score; performs candidate point reservation, elimination or boundary undetermined point marking according to the score, and generates a first purified concentration sequence from the remaining points; obtains a first fitted concentration sequence by deconvolution reconstruction, and performs LB test on a residual sequence; if significant, performs flip verification based on a residual sum of squares improvement range on the boundary undetermined points in descending order of the score, obtains a third purified concentration sequence, and outputs an evaluation report.The application solves the problems of outlier elimination error and deconvolution system deviation through pulse morphological structure perception and residual feedback verification.

This invention discloses a recombinant human growth hormone-collagen fusion protein, its preparation method, and its applications, relating to the field of fusion protein technology. The fusion protein comprises a human growth hormone sequence and a human-like collagen sequence. The amino acid sequence of the fusion protein is shown in SEQ ID NO.7. The first homologous region of the human growth hormone is located at the N-terminus of the fusion protein, and the second homologous region of the human-like collagen is located at the C-terminus. In this invention, recombinant human growth hormone and human collagen with tissue repair function are fused through genetic engineering, achieving efficient expression in the periplasmic space in *E. coli*. High-purity products are obtained by GH affinity chromatography and weak cation exchange chromatography. The protein has a normal structure and good in vitro activity, and can be used to prepare long-acting growth hormone preparations or wound repair materials, showing significant clinical application prospects.

This invention discloses a method for preparing inclusion bodies based on dual-promoter expression plasmids and its application, belonging to the field of biotechnology. The invention includes screening of totipotent nucleases, purification of totipotent nucleases, verification of the degradation activity of the totipotent nuclease DNS on nucleic acids, construction of dual-promoter recombinant strains, fermenter culture, cell recovery, and cell disruption to obtain crude inclusion bodies. This invention achieves high-efficiency expression of the recombinant human growth hormone gene induced by the T7 promoter and high-activity expression of the totipotent nuclease gene DNS induced by the cspA promoter, demonstrating significant effects in the application of recombinant human growth hormone. During the preparation process, the cell viscosity is low, the homogenization and disruption effect is improved, the BL21(DE3) / DGH cell disruption rate is high, the inclusion body content harvested by centrifugation per unit volume of fermentation broth is high, and the residual amount of HCD (host DNA residue) in the target protein per unit mass is reduced, effectively reducing energy consumption.

A method for producing a metabolically activated liver organoid, the method including culturing primary hepatocytes or hepatocyte-like cells in a differentiation medium to obtain a metabolically activated liver organoid, in which the differentiation medium is a medium including one or two selected from the group consisting of a growth hormone receptor agonist and a prolactin receptor agonist, and a glucocorticoid receptor agonist.

The application discloses a probiotic microecological preparation for promoting height growth of children and application thereof, and is characterized by comprising at least one of a fermented Lactobacillus mui ZGG35 strain with a preservation number of CGMCC No. 37997 and a plant Lactobacillus lactis ZGG180 strain with a preservation number of CGMCC No. 37998. The fermented Lactobacillus mui ZGG35 and the plant Lactobacillus lactis ZGG180 are inoculated into a fermentation culture medium at a proportion of 15% in volume ratio to obtain lactic acid bacteria culture, and the ZGG35 bacterial liquid and / or the ZGG180 bacterial liquid is added into a freeze-drying agent to prepare the probiotic microecological preparation. The probiotic microecological preparation has the advantages that the levels of growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein, alkaline phosphatase, osteocalcin, type I procollagen amino-terminal propeptide, insulin, leptin and vitamin D in serum can be improved, and the levels of IL-6 and CTX-I can be reduced.

The application discloses a multi-modal cooperative height-increasing training system and a training method. The system integrates seven modules, including a bioelectricity detection module, a height measurement module, a stimulation module and the like. The measurement component of the height measurement module is an ultrasonic measuring instrument, and the support thereof is adjustable. The bioelectricity detection module collects foot bottom bioelectricity signals and detects the contact state of electrodes. The stimulation module comprises hand and foot electrode pads and a bioelectricity generator, and the support is provided with hand holding rods with hand electrode pads on both sides. The control module is internally provided with an innate ability test program, and five types of exclusive sound waves are matched with an audio output module. Training is carried out in three stages in a progressive manner. Bioelectricity stimulation is combined with foot standing linkage, and five-gear visual feedback is combined to form a closed loop. The application realizes individualized cooperative training, quantifies the effect, activates the pituitary growth hormone, and improves the scientific nature and continuity of training.